Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

V175

Other · developed by Merck Sharp & Dohme LLC

Phase 1 Most advanced trial
MRK Developer

What is V175?

V175 is an agent given by intramuscular administration and studied in lower respiratory tract infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease, Respiratory
Developer
Merck Sharp & Dohme LLC (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Lower Respiratory Tract Infection

More from Merck Sharp & Dohme LLC

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind V175

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.